6.68
Finanzdaten der Nuvectis Pharma Inc-Aktie (NVCT)
Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
Enddatum des Zeitraums | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
Periodenlänge | 3 Monate | 3 Monate | 3 Monate | 3 Monate | 3 Monate |
Research and Development |
1.82%
3.613
|
3.68 | 4.496 | 2.819 | 2.943 |
Operating Income/Loss |
18.44%
-6.595
|
-5.568 | -6.449 | -4.359 | -4.643 |
Income/Loss From Continuing Operations Before Tax |
18.79%
-6.334
|
-5.332 | -6.248 | -4.153 | -4.428 |
Income/Loss From Continuing Operations After Tax |
18.79%
-6.334
|
-5.332 | -6.248 | -4.153 | -4.428 |
|
18.79%
-6.334
|
-5.332 | -6.248 | -4.153 | -4.428 |
Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
Basic Average Shares |
7.17%
21.37
|
19.94 | 0.2151 | 17.23 | 16.90 |
Diluted Average Shares |
7.17%
21.37
|
19.94 | 0.2151 | 17.23 | 16.90 |
Basic Earnings Per Share |
11.11%
-0.30
|
-0.27 | -0.36 | -0.24 | -0.26 |
Diluted Earnings Per Share |
11.11%
-0.30
|
-0.27 | -0.36 | -0.24 | -0.26 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):